Founders Capital Management (Texas)’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-2,000
| Closed | -$2.54K | – | 409 |
|
|
2023
Q3 | $2.54K | Hold |
2,000
| – | – | ﹤0.01% | 363 |
|
|
2023
Q2 | $652 | Hold |
2,000
| – | – | ﹤0.01% | 374 |
|
|
2023
Q1 | $1K | Hold |
2,000
| – | – | ﹤0.01% | 384 |
|
|
2022
Q4 | $1K | Sell |
2,000
-1,000
| -33% | -$634 | ﹤0.01% | 374 |
|
|
2022
Q3 | $2K | Hold |
3,000
| – | – | ﹤0.01% | 371 |
|
|
2022
Q2 | $3K | Hold |
3,000
| – | – | ﹤0.01% | 380 |
|
|
2022
Q1 | $9K | Hold |
3,000
| – | – | 0.01% | 277 |
|
|
2021
Q4 | $9K | Hold |
3,000
| – | – | 0.01% | 277 |
|
|
2021
Q3 | $13K | Buy |
+3,000
| New | +$13.4K | 0.01% | 254 |
|
|
2021
Q1 | – | Sell |
-2,000
| Closed | -$18K | – | 305 |
|
|
2020
Q4 | $18K | Buy |
+2,000
| New | +$7.59K | 0.01% | 205 |
|
|
2020
Q1 | $18K | Buy |
2,000
+1,000
| +100% | +$4.64K | 0.02% | 164 |
|
|
2019
Q4 | $6K | Hold |
1,000
| – | – | ﹤0.01% | 289 |
|
|
2019
Q3 | $8K | Hold |
1,000
| – | – | 0.01% | 270 |
|
|
2019
Q2 | $14K | Hold |
1,000
| – | – | 0.01% | 230 |
|
|
2019
Q1 | $5K | Hold |
1,000
| – | – | ﹤0.01% | 304 |
|
|
2018
Q4 | $3K | Hold |
1,000
| – | – | ﹤0.01% | 320 |
|
|
2018
Q3 | $8K | Buy |
+1,000
| New | +$7.68K | 0.01% | 259 |
|
Founders Capital Management (Texas)'s ZYNE Position: Q4 2023 in Review
Founders Capital Management (Texas) sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2023, closing a stake of 2,000 shares — an estimated $2.54K sold.
Founders Capital Management (Texas) first reported a position in ZYNE in Q3 2018 and held it in 17 quarters. The position peaked at $18K in Q4 2020. 0 funds tracked by Wall St. Rank hold ZYNE as of Q4 2023.
- Founders Capital Management (Texas) reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2023 after selling out during the quarter.
- Founders Capital Management (Texas) sold 2,000 Zynerba Pharmaceuticals, Inc shares in Q4 2023, an estimated $2.54K.
- Founders Capital Management (Texas) first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2018 and held it in 17 quarters.
- Founders Capital Management (Texas)'s Zynerba Pharmaceuticals, Inc position peaked at $18K in Q4 2020.
- 0 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2023.
Based on Founders Capital Management (Texas)'s 13F filing for Q4 2023, filed 8 Jan 2024.